ReviewCurrent oncology reports2005
Immunotherapy for human cancer using heat shock protein-peptide complexes.
Review in Current oncology reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 98 citations in OpenAlex.
- Isoscopoletin inhibits hepatocellular carcinoma cell proliferation via regulating glycolysis-related proteins.PloS one · 2024Article
- Immunosurveillance shapes the emergence of neo-epitope landscapes of sarcomas, revealing prime targets for immunotherapy.JCI insight · 2023Article
- Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development.Cancers · 2022Review
- Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats.Cell stress & chaperones · 2020Article
- Article
- The human HSP70 family of chaperones: where do we stand?Cell stress & chaperones · 2016Review
- Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.PloS one · 2016Article
- Assessment of heat shock protein 70 induction by heat in alfalfa varieties and constitutive overexpression in transgenic plants.PloS one · 2015Article
- Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells.Yonsei medical journal · 2014Article
- Expression and purification of recombinant proteins based on human prostate stem cell antigen and heat shock protein-70.Experimental and therapeutic medicine · 2013Article
- Therapeutic cancer vaccines: past, present, and future.Advances in cancer research · 2013Review
- Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.Journal of skin cancer · 2013Article
- A new purification method for enhancing the immunogenicity of heat shock protein 70-peptide complexes.Oncology reports · 2012Article
- CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity.Cell death & disease · 2012Article
- Expression of heat shock protein 70 in nasopharyngeal carcinomas: different expression patterns correlate with distinct clinical prognosis.Journal of translational medicine · 2012Article
- Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.Expert review of vaccines · 2011Review
- Article
- Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells.Oncogene · 2010Article
- A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat shock proteins (HSPs) are primordial and abundant molecules expressed in all cells. Publications starting in 1984 have shown that immunization of mice, rats, and frogs with purified preparations of selected HSPs isolated from cancers leads to protective immunity against the cancer used as the source of the HSP. The basis of the tumor-specific immunogenicity of these molecules lies not in the molecules themselves but in the array of peptides, including antigenic peptides chaperoned by them. These experiments and the ideas derived from them form the basis of an approach to immunotherapy for human cancer that began in 1995 and is now in full swing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.